"10.1371_journal.pone.0009072","plos one","2010-02-05T00:00:00Z","Yanlan Yu; Pierre Lee; Yaohuang Ke; Yongke Zhang; Qiu Yu; Jonathan Lee; Mingzhen Li; Jialiang Song; Jungang Chen; Jihong Dai; Fernando Jose Rebelo Do Couto; Zhiqiang An; Weimin Zhu; Guo-Liang Yu","Department of Urology, Sir Run-Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China; Epitomics, Inc., Burlingame, California, United States of America; Hangzhou Yikang Biotech, Inc., Hangzhou, People's Republic of China","Conceived and designed the experiments: PL YK YZ FJRDC ZA WZ GLY. Performed the experiments: YY PL YK QY JL ML JS JC JD. Analyzed the data: YY PL YK YZ ZA WZ GLY. Contributed reagents/materials/analysis tools: YY PL YK. Wrote the paper: YY PL YK YZ ZA WZ GLY.","All authors are current or former employees of Epitomics, Inc. or affliated with the company. Epitomics is a biotechnology company which is engaged in the discovery and development of therapeutic antibodies. Epitomics funded the research reported in this manuscript. The research is conducted under the strict scientific methodologies and the internal funding from Epitomics' R&D department does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The leading molecule (Anti-VEGF antibody) is in preclinical development for cancer therapy. The MLG humanization technology described in the manuscript is an issued patent (U.S.Patent 7,462,697).","2010","02","Yanlan Yu","YY",14,TRUE,7,9,7,7,TRUE,TRUE,FALSE,0,NA,FALSE
